Related Experiment Video

Updated: Aug 12, 2026

Coherent anti-Stokes Raman Scattering (CARS) Microscopy Visualizes Pharmaceutical Tablets During Dissolution
09:59

Coherent anti-Stokes Raman Scattering (CARS) Microscopy Visualizes Pharmaceutical Tablets During Dissolution

Published on: July 4, 2014

Influence of phenytoin on theophylline clearance

M Miller, J Cosgriff, T Kwong

    Clinical Pharmacology and Therapeutics
    |May 1, 1984
    PubMed

    More Related Videos

    An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment08:59

    An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

    Published on: December 3, 2020

    Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults14:39

    Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults

    Published on: April 22, 2022

    Related Concept Videos

    Kinetics of Drug Elimination01:17

    Kinetics of Drug Elimination

    Eliminating drugs from the body is a vital process that occurs through excretion or metabolism. Understanding the kinetics of drug elimination is crucial for drug development, dosage determination, and optimizing patient outcomes.
    Drug clearance depends on the rate of drug elimination and its plasma concentration. Another important parameter is the half-life of a drug, which is the time required for its concentration to decrease by half. In most cases, drug clearance follows first-order...
    Hepatic Drug Clearance: Effect of Protein Binding01:09

    Hepatic Drug Clearance: Effect of Protein Binding

    Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
    For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
    Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

    Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

    The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
    A study on guinea pigs examined the...
    Pharmacokinetics: Drug–Drug Interactions01:25

    Pharmacokinetics: Drug–Drug Interactions

    Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
    Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

    Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

    Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
    Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

    Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

    In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...